| Leandra Krowsoski, MD | |
|
100 Woods Rd Ste E-144, Valhalla, NY 10595-1530 | |
| (914) 493-7000 | |
| Not Available |
| Full Name | Leandra Krowsoski |
|---|---|
| Gender | Female |
| Speciality | Surgery - Trauma Surgery |
| Location | 100 Woods Rd Ste E-144, Valhalla, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144535725 | NPI | - | NPPES |
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
Baltimore, MD. The recent findings reported in Nature (March 11, 2004) by Jonathon Tilly's group at Harvard Medical School, show that female mice produce stem cells that give rise to eggs. This result overturns previous notions about mammalian reproduction, which held that females are born with all the eggs that they will ever have and that the decline in egg quality that occurs after a certain age is due to an extended aging process. What mammalian research has not been able to address at this point, however, is how these stem cells operate, what prompts them to develop into eggs, and why they are eventually lost. To answer these questions we must turn to our cousin the fruitfly.
The goal of CliniCloud is to bring healthcare home. For us, what that means is a patient-centered and patient-modeled healthcare system, where we focus on the fact that consumers want access to healthcare and to a doctor. We're building an ecosystem around the tools and the software to really enable that to happen as conveniently and as affordably as possible.
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.
The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.
› Verified 3 days ago
| Entity Name | Westchester Medical Center Advanced Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912131392 PECOS PAC ID: 3173660776 Enrollment ID: O20091031000042 |
News Archive
Baltimore, MD. The recent findings reported in Nature (March 11, 2004) by Jonathon Tilly's group at Harvard Medical School, show that female mice produce stem cells that give rise to eggs. This result overturns previous notions about mammalian reproduction, which held that females are born with all the eggs that they will ever have and that the decline in egg quality that occurs after a certain age is due to an extended aging process. What mammalian research has not been able to address at this point, however, is how these stem cells operate, what prompts them to develop into eggs, and why they are eventually lost. To answer these questions we must turn to our cousin the fruitfly.
The goal of CliniCloud is to bring healthcare home. For us, what that means is a patient-centered and patient-modeled healthcare system, where we focus on the fact that consumers want access to healthcare and to a doctor. We're building an ecosystem around the tools and the software to really enable that to happen as conveniently and as affordably as possible.
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.
The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leandra Krowsoski, MD 100 Woods Rd, Taylor Pavilion, Suite E-144, Valhalla, NY 10595-1530 Ph: (914) 493-7000 | Leandra Krowsoski, MD 100 Woods Rd Ste E-144, Valhalla, NY 10595-1530 Ph: (914) 493-7000 |
News Archive
Baltimore, MD. The recent findings reported in Nature (March 11, 2004) by Jonathon Tilly's group at Harvard Medical School, show that female mice produce stem cells that give rise to eggs. This result overturns previous notions about mammalian reproduction, which held that females are born with all the eggs that they will ever have and that the decline in egg quality that occurs after a certain age is due to an extended aging process. What mammalian research has not been able to address at this point, however, is how these stem cells operate, what prompts them to develop into eggs, and why they are eventually lost. To answer these questions we must turn to our cousin the fruitfly.
The goal of CliniCloud is to bring healthcare home. For us, what that means is a patient-centered and patient-modeled healthcare system, where we focus on the fact that consumers want access to healthcare and to a doctor. We're building an ecosystem around the tools and the software to really enable that to happen as conveniently and as affordably as possible.
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.
The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.
› Verified 3 days ago
Dr. Janis A Pastena, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 100 Woods Road, Nymc Dept. Of Surgery, Munger Pavilion, Valhalla, NY 10595 Phone: 914-261-7319 Fax: 914-593-1802 | |
Roberto Jose Arias Gautreaux, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 100 Woods Rd Rm E-130, Valhalla, NY 10595 Phone: 914-493-7614 | |
Gary Gaspare Lombardo, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Woods Rd, Taylor Pavilion E-135, Valhalla, NY 10595 Phone: 914-493-5213 Fax: 914-493-5271 | |
Dr. Peter Rhee, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Woods Rd, Valhalla, NY 10595 Phone: 914-493-7000 | |
Daniel Jo, Surgery Medicare: Medicare Enrolled Practice Location: 100 Woods Rd, Valhalla, NY 10595 Phone: 914-493-7614 | |
Mr. Arlind Decka, MD Surgery Medicare: Medicare Enrolled Practice Location: 100 Woods Rd, Valhalla, NY 10595 Phone: 914-493-7000 | |
Dr. Chiaka Ogechi Akarichi, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Woods Rd, Valhalla, NY 10595 Phone: 914-493-7000 |